News

Pancreatic Cancer Found to Hijack Nerve Signals to Drive Tumor Growth and Pain

Research Advances /

Researchers have uncovered that pancreatic cancer cells and nearby sensory nerves help each other grow stronger through a chemical signal called glutamate. Sensory nerves release glutamate, and pancreatic cancer cells have a receptor called GRIN2D that detects it. High levels of GRIN2D are linked to more advanced cancer. When cancer cells sense glutamate, they become more […]

Pancreatic Cancer Found to Hijack Nerve Signals to Drive Tumor Growth and Pain Read More »

Personalized Approaches and KRAS Inhibitors Transform Pancreatic Cancer Treatment

Treatment /

Treatment for metastatic pancreatic cancer is becoming more personalized, moving away from a “one-size-fits-all” approach. Doctors now consider patient age, side-effect tolerance, and tumor genetics, such as KRAS mutations, when selecting therapy. NALIRIFOX, approved in 2024, is now a key first-line option. In the NAPOLI 3 trial, it reduced the risk of death by 16%

Personalized Approaches and KRAS Inhibitors Transform Pancreatic Cancer Treatment Read More »

Metastatic Tumor Biopsies Better Predict Immunotherapy Success in Ovarian Cancer

Precision Medicine /

New data from the NeoPembrOV/GINECO trial show that in high-grade serous ovarian cancer, testing PD-L1 levels in metastatic tumors predicts response to immunotherapy better than testing the primary tumor. Patients with high PD-L1 in metastatic sites had a 54% lower risk of disease progression when treated with pembrolizumab plus chemotherapy, while primary tumor PD-L1 was

Metastatic Tumor Biopsies Better Predict Immunotherapy Success in Ovarian Cancer Read More »

Triplet Therapy Shows Promise for Advanced Soft Tissue Sarcoma in Early Study

Treatment /

Interim results from the LINNOVATE study suggest that a combination of lurbinectedin (Zepzelca), ipilimumab (Yervoy), and nivolumab (Opdivo) is highly effective in advanced soft tissue sarcoma. Early data show nearly all patients achieved disease control, with untreated patients seeing some complete or partial responses. The treatment was generally manageable, though 42% of patients experienced severe

Triplet Therapy Shows Promise for Advanced Soft Tissue Sarcoma in Early Study Read More »

Elevar Resubmits Rivoceranib Plus Camrelizumab for FDA Review in Advanced Liver Cancer

Drug Approvals /

Elevar Therapeutics has resubmitted its FDA application for rivoceranib plus camrelizumab as a first-line treatment for unresectable liver cancer (HCC). Previous delays were due to manufacturing and inspection issues, not concerns about the drug’s safety or effectiveness. The Phase 3 CARES-310 trial showed the combination significantly outperformed the former standard, sorafenib. Patients lived a median of

Elevar Resubmits Rivoceranib Plus Camrelizumab for FDA Review in Advanced Liver Cancer Read More »

FDA Reviews Ivonescimab for EGFR-Mutated Lung Cancer After TKI Failure

Drug Approvals /

The FDA has accepted a Biologics License Application for ivonescimab (AK112), a new bispecific antibody for patients with EGFR-mutated, nonsquamous non-small cell lung cancer that has progressed after third-generation TKI treatment. Phase 3 HARMONi trial data from 438 patients showed that ivonescimab combined with chemotherapy significantly slowed disease progression. Median progression-free survival improved from 4.4

FDA Reviews Ivonescimab for EGFR-Mutated Lung Cancer After TKI Failure Read More »

Personalized First-Line Treatments Transform Care for Metastatic Pancreatic Cancer

Precision Medicine /

Treatment for metastatic pancreatic cancer is becoming more personalized, focusing on controlling aggressive disease while considering each patient’s quality of life. Doctors now tailor therapy based on a patient’s ability to tolerate side effects and their tumor’s specific biomarkers, rather than just survival statistics. The FDA-approved NALIRIFOX (2024) adds a new first-line option alongside FOLFIRINOX

Personalized First-Line Treatments Transform Care for Metastatic Pancreatic Cancer Read More »

Elevar Seeks FDA Approval for Targeted Cholangiocarcinoma Drug RLY-4008

Targeted Therapy /

Elevar Therapeutics has asked the FDA to approve lirafugratinib (RLY-4008) as a second-line treatment for cholangiocarcinoma, a rare bile duct cancer, in patients with FGFR2 gene changes. The request is based on the ReFocus trial, which included 116 patients who had already had chemotherapy but not another FGFR-targeted drug. The drug showed a 46.5% overall

Elevar Seeks FDA Approval for Targeted Cholangiocarcinoma Drug RLY-4008 Read More »

EMA Backs Targeted Akeega Therapy for BRCA-Mutated Prostate Cancer

Targeted Therapy /

European regulators have given a positive recommendation to expand the use of Akeega, a combination of niraparib and abiraterone, for patients with metastatic hormone-sensitive prostate cancer who carry BRCA1 or BRCA2 mutations. If approved, this pill—taken with prednisone and standard hormone therapy—would offer a targeted treatment option earlier in the disease, based on a patient’s

EMA Backs Targeted Akeega Therapy for BRCA-Mutated Prostate Cancer Read More »

Cervical Cancer: Highly Preventable, Yet Still a Global Health Threat

News /

Cervical cancer is highly preventable, yet it remains a major global health issue. Worldwide, it is the fourth most common cancer in women, causing over 600,000 new cases and about 350,000 deaths each year. In the United States, roughly 13,500 new cases and more than 4,000 deaths occur annually. Overall five-year survival is about 67%,

Cervical Cancer: Highly Preventable, Yet Still a Global Health Threat Read More »